|Articles|April 21, 2016
FDA's Breakthrough Designation is Working, Says Report
April 21, 2016.
Advertisement
The good news about FDA’s breakthrough drug initiative is that it actually appears to be accelerating clinical development of highly promising new therapies, according to recent analysis by Friends of Cancer Research (FOCR) .
Read Jill Wechsler's view in
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly and Novo Nordisk Bring Weight-Loss Medications to TrumpRx
2
FDA Approves Johnson and Johnson’s Caplyta
3
Pharmaceutical Executive Daily: Novo Nordisk's Amended Acquisition Proposal
4
Pharma’s Next Commercial Frontier: Orchestrating Data, AI, and CRM for True Customer Centricity
5
